351 related articles for article (PubMed ID: 32873270)
1. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
3. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
[TBL] [Abstract][Full Text] [Related]
7. Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.
Yamauchi M; Minesaki A; Ishida T; Sato Y; Okamura S; Shuto H; Tanaka N; Hatayama E; Shibamiya N; Kuratomi Y
In Vivo; 2023; 37(3):1275-1280. PubMed ID: 37103108
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
9. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
Sun Y; Guo W; Bai Y; Ge M; Hu C; Wu S; Hao J; Gao M; Pan J; Dong P; Wu Y; Liang H; Wei Q; Zhong M; Lu T
Oral Dis; 2020 Mar; 26(2):285-294. PubMed ID: 31830347
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Shirasu H; Yokota T; Kawakami T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Mori K; Onitsuka T
Int J Clin Oncol; 2020 Nov; 25(11):1914-1920. PubMed ID: 32648132
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Oertel K; Spiegel K; Schmalenberg H; Dietz A; Maschmeyer G; Kuhnt T; Sudhoff H; Wendt TG; Guntinas-Lichius O
BMC Cancer; 2012 Oct; 12():483. PubMed ID: 23083061
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer.
Wang HM; Lin CY; Hsieh CH; Hsu CL; Fan KH; Chang JT; Huang SF; Kang CJ; Liao CT; Ng SH; Yen TC
J Formos Med Assoc; 2017 Mar; 116(3):185-192. PubMed ID: 27133181
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Watanabe A; Taniguchi M; Sasaki S
Anticancer Drugs; 2003 Nov; 14(10):801-7. PubMed ID: 14597874
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
[TBL] [Abstract][Full Text] [Related]
20. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
